TY - JOUR AU - Blennow, K. AU - Leon, M. J. AU - Zetterberg, H. PY - 2006 DA - 2006// TI - Alzheimer’s disease JO - Lancet VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69113-7 DO - 10.1016/S0140-6736(06)69113-7 ID - Blennow2006 ER - TY - JOUR AU - Bloom, G. S. PY - 2014 DA - 2014// TI - Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis JO - JAMA Neurol VL - 71 ID - Bloom2014 ER - TY - JOUR AU - Bertram, L. AU - Lill, C. M. AU - Tanzi, R. E. PY - 2010 DA - 2010// TI - The genetics of Alzheimer disease: back to the future JO - Neuron VL - 68 UR - https://doi.org/10.1016/j.neuron.2010.10.013 DO - 10.1016/j.neuron.2010.10.013 ID - Bertram2010 ER - TY - JOUR AU - Wiseman, F. K. AU - Al-Janabi, T. AU - Hardy, J. AU - Karmiloff-Smith, A. AU - Nizetic, D. AU - Tybulewicz, V. L. PY - 2015 DA - 2015// TI - A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome JO - Nat Rev Neurosci VL - 16 UR - https://doi.org/10.1038/nrn3983 DO - 10.1038/nrn3983 ID - Wiseman2015 ER - TY - JOUR AU - Rovelet-Lecrux, A. AU - Hannequin, D. AU - Raux, G. AU - Meur, N. AU - Laquerriere, A. AU - Vital, A. PY - 2006 DA - 2006// TI - APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy JO - Nat Genet VL - 38 UR - https://doi.org/10.1038/ng1718 DO - 10.1038/ng1718 ID - Rovelet-Lecrux2006 ER - TY - JOUR AU - Strittmatter, W. J. AU - Weisgraber, K. H. AU - Huang, D. Y. AU - Dong, L. M. AU - Salvesen, G. S. AU - Pericak-Vance, M. PY - 1993 DA - 1993// TI - Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease JO - Proc Natl Acad Sci U S A VL - 90 UR - https://doi.org/10.1073/pnas.90.17.8098 DO - 10.1073/pnas.90.17.8098 ID - Strittmatter1993 ER - TY - JOUR AU - Brothers, H. M. AU - Gosztyla, M. L. AU - Robinson, S. R. PY - 2018 DA - 2018// TI - The physiological roles of amyloid-beta peptide hint at new ways to treat Alzheimer’s disease JO - Front Aging Neurosci VL - 10 UR - https://doi.org/10.3389/fnagi.2018.00118 DO - 10.3389/fnagi.2018.00118 ID - Brothers2018 ER - TY - JOUR AU - Pernegre, C. AU - Duquette, A. AU - Leclerc, N. PY - 2019 DA - 2019// TI - Tau secretion: good and bad for neurons JO - Front Neurosci VL - 13 UR - https://doi.org/10.3389/fnins.2019.00649 DO - 10.3389/fnins.2019.00649 ID - Pernegre2019 ER - TY - JOUR AU - Andreasen, N. AU - Blennow, K. PY - 2005 DA - 2005// TI - CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease JO - Clin Neurol Neurosurg VL - 107 UR - https://doi.org/10.1016/j.clineuro.2004.10.011 DO - 10.1016/j.clineuro.2004.10.011 ID - Andreasen2005 ER - TY - JOUR AU - Blennow, K. AU - Hampel, H. PY - 2003 DA - 2003// TI - CSF markers for incipient Alzheimer’s disease JO - Lancet Neurol VL - 2 UR - https://doi.org/10.1016/S1474-4422(03)00530-1 DO - 10.1016/S1474-4422(03)00530-1 ID - Blennow2003 ER - TY - JOUR AU - McKhann, G. M. AU - Knopman, D. S. AU - Chertkow, H. AU - Hyman, B. T. AU - Jack, C. R. AU - Kawas, C. H. PY - 2011 DA - 2011// TI - The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease JO - Alzheimers Dement VL - 7 UR - https://doi.org/10.1016/j.jalz.2011.03.005 DO - 10.1016/j.jalz.2011.03.005 ID - McKhann2011 ER - TY - JOUR AU - Dubois, B. AU - Feldman, H. H. AU - Jacova, C. AU - Hampel, H. AU - Molinuevo, J. L. AU - Blennow, K. PY - 2014 DA - 2014// TI - Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70090-0 DO - 10.1016/S1474-4422(14)70090-0 ID - Dubois2014 ER - TY - JOUR AU - Gabelle, A. AU - Dumurgier, J. AU - Vercruysse, O. AU - Paquet, C. AU - Bombois, S. AU - Laplanche, J. L. PY - 2013 DA - 2013// TI - Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study JO - J Alzheimers Dis VL - 34 UR - https://doi.org/10.3233/JAD-121549 DO - 10.3233/JAD-121549 ID - Gabelle2013 ER - TY - STD TI - Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2015;11:58–69. ID - ref14 ER - TY - JOUR AU - Lewczuk, P. AU - Kornhuber, J. AU - Toledo, J. B. AU - Trojanowski, J. Q. AU - Knapik-Czajka, M. AU - Peters, O. PY - 2015 DA - 2015// TI - Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer’s disease in pre-dementia subjects JO - J Alzheimers Dis VL - 48 UR - https://doi.org/10.3233/JAD-150342 DO - 10.3233/JAD-150342 ID - Lewczuk2015 ER - TY - JOUR AU - Nordberg, A. PY - 2004 DA - 2004// TI - PET imaging of amyloid in Alzheimer’s disease JO - Lancet Neurol VL - 3 UR - https://doi.org/10.1016/S1474-4422(04)00853-1 DO - 10.1016/S1474-4422(04)00853-1 ID - Nordberg2004 ER - TY - JOUR AU - Villemagne, V. L. AU - Fodero-Tavoletti, M. T. AU - Masters, C. L. AU - Rowe, C. C. PY - 2015 DA - 2015// TI - Tau imaging: early progress and future directions JO - Lancet Neurol VL - 14 UR - https://doi.org/10.1016/S1474-4422(14)70252-2 DO - 10.1016/S1474-4422(14)70252-2 ID - Villemagne2015 ER - TY - JOUR AU - Jack, C. R. AU - Wiste, H. J. AU - Vemuri, P. AU - Weigand, S. D. AU - Senjem, M. L. AU - Zeng, G. PY - 2010 DA - 2010// TI - Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease JO - Brain VL - 133 UR - https://doi.org/10.1093/brain/awq277 DO - 10.1093/brain/awq277 ID - Jack2010 ER - TY - JOUR AU - Gabelle, A. AU - Roche, S. AU - Geny, C. AU - Bennys, K. AU - Labauge, P. AU - Tholance, Y. PY - 2010 DA - 2010// TI - Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid JO - Brain Res VL - 1357 UR - https://doi.org/10.1016/j.brainres.2010.08.022 DO - 10.1016/j.brainres.2010.08.022 ID - Gabelle2010 ER - TY - JOUR AU - Dorey, A. AU - Perret-Liaudet, A. AU - Tholance, Y. AU - Fourier, A. AU - Quadrio, I. PY - 2015 DA - 2015// TI - Cerebrospinal fluid Abeta40 improves the interpretation of Abeta42 concentration for diagnosing Alzheimer’s disease JO - Front Neurol VL - 6 UR - https://doi.org/10.3389/fneur.2015.00247 DO - 10.3389/fneur.2015.00247 ID - Dorey2015 ER - TY - JOUR AU - Lewczuk, P. AU - Esselmann, H. AU - Otto, M. AU - Maler, J. M. AU - Henkel, A. W. AU - Henkel, M. K. PY - 2004 DA - 2004// TI - Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau JO - Neurobiol Aging VL - 25 UR - https://doi.org/10.1016/S0197-4580(03)00086-1 DO - 10.1016/S0197-4580(03)00086-1 ID - Lewczuk2004 ER - TY - JOUR AU - Lehmann, S. AU - Delaby, C. AU - Boursier, G. AU - Catteau, C. AU - Ginestet, N. AU - Tiers, L. PY - 2018 DA - 2018// TI - Relevance of Abeta42/40 ratio for detection of Alzheimer disease pathology in clinical routine: the PLMR scale JO - Front Aging Neurosci VL - 10 UR - https://doi.org/10.3389/fnagi.2018.00138 DO - 10.3389/fnagi.2018.00138 ID - Lehmann2018 ER - TY - JOUR AU - Gervaise-Henry, C. AU - Watfa, G. AU - Albuisson, E. AU - Kolodziej, A. AU - Dousset, B. AU - Olivier, J. L. PY - 2017 DA - 2017// TI - Cerebrospinal fluid Abeta42/Abeta40 as a means to limiting tube- and storage-dependent pre-analytical variability in clinical setting JO - J Alzheimers Dis VL - 57 UR - https://doi.org/10.3233/JAD-160865 DO - 10.3233/JAD-160865 ID - Gervaise-Henry2017 ER - TY - JOUR AU - Lewczuk, P. AU - Lelental, N. AU - Spitzer, P. AU - Maler, J. M. AU - Kornhuber, J. PY - 2015 DA - 2015// TI - Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer’s disease: validation of two novel assays JO - J Alzheimers Dis VL - 43 UR - https://doi.org/10.3233/JAD-140771 DO - 10.3233/JAD-140771 ID - Lewczuk2015 ER - TY - JOUR AU - Willemse, E. AU - Uffelen, K. AU - Brix, B. AU - Engelborghs, S. AU - Vanderstichele, H. AU - Teunissen, C. PY - 2017 DA - 2017// TI - How to handle adsorption of cerebrospinal fluid amyloid beta (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Abeta42/Abeta40 ratio JO - Alzheimers Dement VL - 13 UR - https://doi.org/10.1016/j.jalz.2017.01.010 DO - 10.1016/j.jalz.2017.01.010 ID - Willemse2017 ER - TY - JOUR AU - Hansson, O. AU - Lehmann, S. AU - Otto, M. AU - Zetterberg, H. AU - Lewczuk, P. PY - 2019 DA - 2019// TI - Advantages and disadvantages of the use of the CSF amyloid beta (Abeta) 42/40 ratio in the diagnosis of Alzheimer’s disease JO - Alzheimers Res Ther VL - 11 UR - https://doi.org/10.1186/s13195-019-0485-0 DO - 10.1186/s13195-019-0485-0 ID - Hansson2019 ER - TY - JOUR AU - Dumurgier, J. AU - Schraen, S. AU - Gabelle, A. AU - Vercruysse, O. AU - Bombois, S. AU - Laplanche, J. L. PY - 2015 DA - 2015// TI - Cerebrospinal fluid amyloid-beta 42/40 ratio in clinical setting of memory centers: a multicentric study JO - Alzheimers Res Ther VL - 7 UR - https://doi.org/10.1186/s13195-015-0114-5 DO - 10.1186/s13195-015-0114-5 ID - Dumurgier2015 ER - TY - JOUR AU - Wiltfang, J. AU - Esselmann, H. AU - Bibl, M. AU - Hull, M. AU - Hampel, H. AU - Kessler, H. PY - 2007 DA - 2007// TI - Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load JO - J Neurochem VL - 101 UR - https://doi.org/10.1111/j.1471-4159.2006.04404.x DO - 10.1111/j.1471-4159.2006.04404.x ID - Wiltfang2007 ER - TY - JOUR AU - Bibl, M. AU - Mollenhauer, B. AU - Lewczuk, P. AU - Esselmann, H. AU - Wolf, S. AU - Otto, M. PY - 2011 DA - 2011// TI - Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias JO - Dement Geriatr Cogn Disord VL - 31 UR - https://doi.org/10.1159/000322370 DO - 10.1159/000322370 ID - Bibl2011 ER - TY - JOUR AU - Gabelle, A. AU - Roche, S. AU - Geny, C. AU - Bennys, K. AU - Labauge, P. AU - Tholance, Y. PY - 2011 DA - 2011// TI - Decreased sAbetaPPbeta, Abeta38, and Abeta40 cerebrospinal fluid levels in frontotemporal dementia JO - J Alzheimers Dis VL - 26 UR - https://doi.org/10.3233/JAD-2011-110515 DO - 10.3233/JAD-2011-110515 ID - Gabelle2011 ER - TY - STD TI - Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol. 2012;259:2429–33. ID - ref31 ER - TY - JOUR AU - Gisslen, M. AU - Krut, J. AU - Andreasson, U. AU - Blennow, K. AU - Cinque, P. AU - Brew, B. J. PY - 2009 DA - 2009// TI - Amyloid and tau cerebrospinal fluid biomarkers in HIV infection JO - BMC Neurol VL - 9 UR - https://doi.org/10.1186/1471-2377-9-63 DO - 10.1186/1471-2377-9-63 ID - Gisslen2009 ER - TY - JOUR AU - Pietroboni, A. M. AU - Caprioli, M. AU - Carandini, T. AU - Scarioni, M. AU - Ghezzi, L. AU - Arighi, A. PY - 2019 DA - 2019// TI - CSF beta-amyloid predicts prognosis in patients with multiple sclerosis JO - Mult Scler VL - 25 UR - https://doi.org/10.1177/1352458518791709 DO - 10.1177/1352458518791709 ID - Pietroboni2019 ER - TY - JOUR AU - Chen, Z. AU - Liu, C. AU - Zhang, J. AU - Relkin, N. AU - Xing, Y. AU - Li, Y. PY - 2017 DA - 2017// TI - Cerebrospinal fluid Abeta42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis JO - Fluids Barriers CNS VL - 14 UR - https://doi.org/10.1186/s12987-017-0062-5 DO - 10.1186/s12987-017-0062-5 ID - Chen2017 ER - TY - JOUR AU - Olsson, B. AU - Lautner, R. AU - Andreasson, U. AU - Öhrfelt, A. AU - Portelius, E. AU - Bjerke, M. PY - 2016 DA - 2016// TI - CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis JO - Lancet Neurol VL - 15 UR - https://doi.org/10.1016/S1474-4422(16)00070-3 DO - 10.1016/S1474-4422(16)00070-3 ID - Olsson2016 ER - TY - JOUR AU - Alcolea, D. AU - Martinez-Lage, P. AU - Sanchez-Juan, P. AU - Olazaran, J. AU - Antunez, C. AU - Izagirre, A. PY - 2015 DA - 2015// TI - Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease JO - Neurology VL - 85 UR - https://doi.org/10.1212/WNL.0000000000001859 DO - 10.1212/WNL.0000000000001859 ID - Alcolea2015 ER - TY - JOUR AU - Sala, I. AU - Illan-Gala, I. AU - Alcolea, D. AU - Sanchez-Saudinos, M. B. AU - Salgado, S. A. AU - Morenas-Rodriguez, E. PY - 2017 DA - 2017// TI - Diagnostic and prognostic value of the combination of two measures of verbal memory in mild cognitive impairment due to Alzheimer’s disease JO - J Alzheimers Dis VL - 58 UR - https://doi.org/10.3233/JAD-170073 DO - 10.3233/JAD-170073 ID - Sala2017 ER - TY - JOUR AU - McKhann, G. M. AU - Albert, M. S. AU - Grossman, M. AU - Miller, B. AU - Dickson, D. AU - Trojanowski, J. Q. PY - 2001 DA - 2001// TI - Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease JO - Arch Neurol VL - 58 UR - https://doi.org/10.1001/archneur.58.11.1803 DO - 10.1001/archneur.58.11.1803 ID - McKhann2001 ER - TY - JOUR AU - McKeith, I. G. PY - 2006 DA - 2006// TI - Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop JO - J Alzheimers Dis VL - 9 UR - https://doi.org/10.3233/JAD-2006-9S347 DO - 10.3233/JAD-2006-9S347 ID - McKeith2006 ER - TY - JOUR AU - Boeve, B. F. AU - Maraganore, D. M. AU - Parisi, J. E. AU - Ahlskog, J. E. AU - Graff-Radford, N. AU - Caselli, R. J. PY - 1999 DA - 1999// TI - Pathologic heterogeneity in clinically diagnosed corticobasal degeneration JO - Neurology VL - 53 UR - https://doi.org/10.1212/WNL.53.4.795 DO - 10.1212/WNL.53.4.795 ID - Boeve1999 ER - TY - JOUR AU - Lehmann, S. AU - Schraen, S. AU - Paquet, C. AU - Bombois, S. AU - Delaby, C. AU - Dorey, A. PY - 2014 DA - 2014// TI - A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles JO - Alzheimers Res Ther VL - 6 UR - https://doi.org/10.1186/alzrt267 DO - 10.1186/alzrt267 ID - Lehmann2014 ER - TY - JOUR AU - Dumurgier, J. AU - Vercruysse, O. AU - Paquet, C. AU - Bombois, S. AU - Chaulet, C. AU - Laplanche, J. L. PY - 2013 DA - 2013// TI - Intersite variability of CSF Alzheimer’s disease biomarkers in clinical setting JO - Alzheimers Dement VL - 9 UR - https://doi.org/10.1016/j.jalz.2012.06.006 DO - 10.1016/j.jalz.2012.06.006 ID - Dumurgier2013 ER - TY - JOUR AU - Campo, M. AU - Mollenhauer, B. AU - Bertolotto, A. AU - Engelborghs, S. AU - Hampel, H. AU - Simonsen, A. H. PY - 2012 DA - 2012// TI - Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update JO - Biomark Med VL - 6 UR - https://doi.org/10.2217/bmm.12.46 DO - 10.2217/bmm.12.46 ID - Campo2012 ER - TY - JOUR AU - Barthelemy, N. R. AU - Li, Y. AU - Joseph-Mathurin, N. AU - Gordon, B. A. AU - Hassenstab, J. AU - Benzinger, T. L. S. PY - 2020 DA - 2020// TI - A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease JO - Nat Med VL - 26 UR - https://doi.org/10.1038/s41591-020-0781-z DO - 10.1038/s41591-020-0781-z ID - Barthelemy2020 ER - TY - JOUR AU - Hansson, O. AU - Seibyl, J. AU - Stomrud, E. AU - Zetterberg, H. AU - Trojanowski, J. Q. AU - Bittner, T. PY - 2018 DA - 2018// TI - CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts JO - Alzheimers Dement VL - 14 UR - https://doi.org/10.1016/j.jalz.2018.01.010 DO - 10.1016/j.jalz.2018.01.010 ID - Hansson2018 ER - TY - JOUR AU - Spellman, D. S. AU - Wildsmith, K. R. AU - Honigberg, L. A. AU - Tuefferd, M. AU - Baker, D. AU - Raghavan, N. PY - 2015 DA - 2015// TI - Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF JO - Proteomics Clin Appl VL - 9 UR - https://doi.org/10.1002/prca.201400178 DO - 10.1002/prca.201400178 ID - Spellman2015 ER - TY - JOUR AU - Perret-Liaudet, A. AU - Pelpel, M. AU - Tholance, Y. AU - Dumont, B. AU - Vanderstichele, H. AU - Zorzi, W. PY - 2012 DA - 2012// TI - Risk of Alzheimer’s disease biological misdiagnosis linked to cerebrospinal collection tubes JO - J Alzheimers Dis VL - 31 UR - https://doi.org/10.3233/JAD-2012-120361 DO - 10.3233/JAD-2012-120361 ID - Perret-Liaudet2012 ER - TY - JOUR AU - Renard, D. AU - Wacongne, A. AU - Ayrignac, X. AU - Charif, M. AU - Fourcade, G. AU - Azakri, S. PY - 2015 DA - 2015// TI - Cerebrospinal fluid Alzheimer’s disease biomarkers in cerebral amyloid angiopathy-related inflammation JO - J Alzheimers Dis VL - 50 UR - https://doi.org/10.3233/JAD-150621 DO - 10.3233/JAD-150621 ID - Renard2015 ER - TY - JOUR AU - Peskind, E. R. AU - Li, G. AU - Shofer, J. AU - Quinn, J. F. AU - Kaye, J. A. AU - Clark, C. M. PY - 2006 DA - 2006// TI - Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition JO - Arch Neurol VL - 63 UR - https://doi.org/10.1001/archneur.63.7.936 DO - 10.1001/archneur.63.7.936 ID - Peskind2006 ER - TY - JOUR AU - Sunderland, T. AU - Mirza, N. AU - Putnam, K. T. AU - Linker, G. AU - Bhupali, D. AU - Durham, R. PY - 2004 DA - 2004// TI - Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele JO - Biol Psychiatry VL - 56 UR - https://doi.org/10.1016/j.biopsych.2004.07.021 DO - 10.1016/j.biopsych.2004.07.021 ID - Sunderland2004 ER - TY - STD TI - Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, et al. Observatoire Francais de la Sclerose en Plaques (OFSEP): a unique multimodal nationwide MS registry in France. Mult Scler. 2020;26:118–22. ID - ref51 ER - TY - JOUR AU - Marelli, C. AU - Gutierrez, L. A. AU - Menjot de Champfleur, N. AU - Charroud, C. AU - Verbizier, D. AU - Touchon, J. PY - 2015 DA - 2015// TI - Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer’s disease: interest of cerebrospinal fluid biomarker ratios JO - Alzheimers Dement (Amst) VL - 1 UR - https://doi.org/10.1016/j.dadm.2015.06.004 DO - 10.1016/j.dadm.2015.06.004 ID - Marelli2015 ER - TY - JOUR AU - Janelidze, S. AU - Zetterberg, H. AU - Mattsson, N. AU - Palmqvist, S. AU - Vanderstichele, H. AU - Lindberg, O. PY - 2016 DA - 2016// TI - CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: better diagnostic markers of Alzheimer disease JO - Ann Clin Transl Neurol VL - 3 UR - https://doi.org/10.1002/acn3.274 DO - 10.1002/acn3.274 ID - Janelidze2016 ER - TY - JOUR AU - Welge, V. AU - Fiege, O. AU - Lewczuk, P. AU - Mollenhauer, B. AU - Esselmann, H. AU - Klafki, H. W. PY - 2009 DA - 2009// TI - Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer’s disease JO - J Neural Transm VL - 116 UR - https://doi.org/10.1007/s00702-008-0177-6 DO - 10.1007/s00702-008-0177-6 ID - Welge2009 ER - TY - JOUR AU - Sundelof, J. AU - Sundstrom, J. AU - Hansson, O. AU - Eriksdotter-Jonhagen, M. AU - Giedraitis, V. AU - Larsson, A. PY - 2010 DA - 2010// TI - Higher cathepsin B levels in plasma in Alzheimer’s disease compared to healthy controls JO - J Alzheimers Dis VL - 22 UR - https://doi.org/10.3233/JAD-2010-101023 DO - 10.3233/JAD-2010-101023 ID - Sundelof2010 ER - TY - JOUR AU - Lewczuk, P. AU - Matzen, A. AU - Blennow, K. AU - Parnetti, L. AU - Molinuevo, J. L. AU - Eusebi, P. PY - 2017 DA - 2017// TI - Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease JO - J Alzheimers Dis VL - 55 UR - https://doi.org/10.3233/JAD-160722 DO - 10.3233/JAD-160722 ID - Lewczuk2017 ER - TY - JOUR AU - Tijms, B. M. AU - Vermunt, L. AU - Zwan, M. D. AU - Harten, A. C. AU - Flier, W. M. AU - Teunissen, C. E. PY - 2018 DA - 2018// TI - Pre-amyloid stage of Alzheimer’s disease in cognitively normal individuals JO - Ann Clin Transl Neurol VL - 5 UR - https://doi.org/10.1002/acn3.615 DO - 10.1002/acn3.615 ID - Tijms2018 ER - TY - JOUR AU - Janelidze, S. AU - Pannee, J. AU - Mikulskis, A. AU - Chiao, P. AU - Zetterberg, H. AU - Blennow, K. PY - 2017 DA - 2017// TI - Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment JO - JAMA Neurol VL - 74 UR - https://doi.org/10.1001/jamaneurol.2017.2814 DO - 10.1001/jamaneurol.2017.2814 ID - Janelidze2017 ER - TY - JOUR AU - Nakamura, A. AU - Kaneko, N. AU - Villemagne, V. L. AU - Kato, T. AU - Doecke, J. AU - Dore, V. PY - 2018 DA - 2018// TI - High performance plasma amyloid-beta biomarkers for Alzheimer’s disease JO - Nature VL - 554 UR - https://doi.org/10.1038/nature25456 DO - 10.1038/nature25456 ID - Nakamura2018 ER - TY - STD TI - Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Treluyer JM, et al. Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers. Alzheimers Dement. 2018. ID - ref60 ER - TY - STD TI - Gabelle A, Schraen S, Gutierrez LA, Pays C, Rouaud O, Buee L, et al. Plasma beta-amyloid 40 levels are positively associated with mortality risks in the elderly. Alzheimers Dement. 2018;14:858–68. ID - ref61 ER - TY - JOUR AU - Simic, G. AU - Babic Leko, M. AU - Wray, S. AU - Harrington, C. AU - Delalle, I. AU - Jovanov-Milosevic, N. PY - 2016 DA - 2016// TI - Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies JO - Biomolecules VL - 6 UR - https://doi.org/10.3390/biom6010006 DO - 10.3390/biom6010006 ID - Simic2016 ER - TY - JOUR AU - Martin, L. AU - Latypova, X. AU - Terro, F. PY - 2011 DA - 2011// TI - Post-translational modifications of tau protein: implications for Alzheimer’s disease JO - Neurochem Int VL - 58 UR - https://doi.org/10.1016/j.neuint.2010.12.023 DO - 10.1016/j.neuint.2010.12.023 ID - Martin2011 ER - TY - JOUR AU - Selenica, M. L. AU - Brownlow, M. AU - Jimenez, J. P. AU - Lee, D. C. AU - Pena, G. AU - Dickey, C. A. PY - 2013 DA - 2013// TI - Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy JO - Neurodegener Dis VL - 11 UR - https://doi.org/10.1159/000337230 DO - 10.1159/000337230 ID - Selenica2013 ER -